Aa
Treatment of pegylated-interferon alfa-2a in CHB
Treatment of pegylated-interferon alfa-2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation
BACKGROUND:
Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV-DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated-interferon alfa-2a (PEG-IFNα2a) for such CHB patients.
METHODS:
Seventy-four HBeAg-positive patients with a spontaneous HBV-DNA decline (by >2 log(10) IU•mL-1, compared to baseline levels before antiviral treatment) after AE (alanine aminotransferase ALT: 10-30-fold the upper limit of normal ULN, total bilirubin TBIL: 2-20 mg•mL-1, prothrombin time activity >60%) were included. Twenty-two patients (group A) received PEG-IFNα2a treatment (180 µg•kg-1•week-1, when ALT was <10ULN and TBIL <2 mg•mL-1) for 48 weeks, with 48 weeks of treatment-free follow-up. Twenty-one patients (group B) selected continual entecavir therapy. Thirty-one patients (group C, control group) received routine liver-protective drugs.
RESULTS:
At week 96, virological response rates were 90.5%, 100%, and 48%, and ALT normalization rates were 81%, 95%, and 40% for groups A, B, and C, respectively. HBeAg seroconversion rates were 71.4%, 45%, and 32% in groups A, B, and C, respectively. A high HBsAg loss rate was observed in PEG-IFNα2a-treated patients, while no entecavir-treated patients achieved HBsAg loss. Group A patients suffered from typical pegylated-interferon therapy-related adverse events. No severe adverse event was observed in any groups.
CONCLUSIONS:
PEG-IFNα2a is effective and safe for treating CHB patients demonstrating a spontaneous decline in HBV DNA after AE, and yields an increased likelihood of HBsAg loss.
http://www.ncbi.nlm.nih.gov/pubmed/25138110
BACKGROUND:
Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV-DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated-interferon alfa-2a (PEG-IFNα2a) for such CHB patients.
METHODS:
Seventy-four HBeAg-positive patients with a spontaneous HBV-DNA decline (by >2 log(10) IU•mL-1, compared to baseline levels before antiviral treatment) after AE (alanine aminotransferase ALT: 10-30-fold the upper limit of normal ULN, total bilirubin TBIL: 2-20 mg•mL-1, prothrombin time activity >60%) were included. Twenty-two patients (group A) received PEG-IFNα2a treatment (180 µg•kg-1•week-1, when ALT was <10ULN and TBIL <2 mg•mL-1) for 48 weeks, with 48 weeks of treatment-free follow-up. Twenty-one patients (group B) selected continual entecavir therapy. Thirty-one patients (group C, control group) received routine liver-protective drugs.
RESULTS:
At week 96, virological response rates were 90.5%, 100%, and 48%, and ALT normalization rates were 81%, 95%, and 40% for groups A, B, and C, respectively. HBeAg seroconversion rates were 71.4%, 45%, and 32% in groups A, B, and C, respectively. A high HBsAg loss rate was observed in PEG-IFNα2a-treated patients, while no entecavir-treated patients achieved HBsAg loss. Group A patients suffered from typical pegylated-interferon therapy-related adverse events. No severe adverse event was observed in any groups.
CONCLUSIONS:
PEG-IFNα2a is effective and safe for treating CHB patients demonstrating a spontaneous decline in HBV DNA after AE, and yields an increased likelihood of HBsAg loss.
http://www.ncbi.nlm.nih.gov/pubmed/25138110
i assure you that StephenCastlecrag is an hbv patient
......and also that nucs will clear hbv and will not need indefinite treatment probably in 90% of patients by 10-15years and this without use of peginterferon add on
......and also that nucs will clear hbv and will not need indefinite treatment probably in 90% of patients by 10-15years and this without use of peginterferon add on
Sorry Stephen,
I could not access in order to read the whole paper. :(
I could not access in order to read the whole paper. :(
You dont sound like a real HBV patient. :) but sorry I forgot indefinite nucs treatment we all need.
Interferon all the way always was. And will be before they release Replicor.
Interferon all the way always was. And will be before they release Replicor.
This is interesting, supporting the old concept of using Interferon only when immune system is active. However, it would be nice to know when the AE (acute exacerbation) occurs, when the patients were on Entecavir treatment?
It would also be nice to know how many in group A seroconverted their s-antigen.
It would also be nice to know how many in group A seroconverted their s-antigen.
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
